查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024608

RNA干擾藥物遞送市場報告：按應用、技術和地區分類，2026-2034年

RNA Interference Drug Delivery Market Report by Application, Technology, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球RNA干擾（RNAi）藥物遞送市場規模達1,175億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到5,042億美元，2026年至2034年的複合年成長率為17.04%。

RNAi藥物傳遞是指用於監測基因表現和突變的治療方案。 RNAi藥物傳遞通常透過靜脈注射、皮內注射、腹腔注射或局部給藥。這包括使用奈米顆粒、核酸和適配體的藥物遞送技術。這些技術也用於分析真核生物的基因功能以及開發治療性基因靜默方案。因此，RNAi藥物傳遞技術被廣泛應用於感染疾病、慢性代謝性疾病、心血管疾病、泌尿系統疾病、泌尿系統疾病、腫瘤疾病和眼科疾病的治療。

全球範圍內慢性病和遺傳性疾病（例如癌症和心血管疾病）盛行率的不斷上升是推動市場成長的主要因素。此外，老年人口的成長（他們更容易患上這些疾病）也促進了市場成長。同時，隨著新冠肺炎疫情在全球持續蔓延，對RNAi藥物傳遞技術的需求顯著增加。標靶遞送方法，例如適體藥物遞送系統，因其利用小感染疾病RNA（siRNA）抑制病毒抗原表達，在抗病毒藥物治療領域備受關注。此外，包括創新合成遞送載體和生物載體的開發在內的各種技術進步，預計也將推動市場成長。奈米載體，包括siRNA和微型RNA（miRNA），對於個人化醫療的發展以及識別細胞分子和代謝物的改變至關重要。奈米技術和分子診斷領域的廣泛研發活動，以及整體醫療保健基礎設施的改善等其他因素，預計也將進一步推動市場發展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球RNA干擾藥物傳遞​​市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依應用領域分類

  • 感染疾病
  • 循環系統
  • 腫瘤學
  • 神經病學
  • 眼科
  • 泌尿系統
  • 代謝性疾病
  • 其他

第7章 市場區隔：依技術分類

  • 奈米顆粒藥物遞送
  • 肺部藥物遞送
  • 核酸藥物遞送
  • 適體藥物遞送

第8章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章 SWOT 分析

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Alnylam Pharmaceuticals, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Calando Pharmaceuticals Inc
    • Ionis Pharmaceuticals, Inc.
    • Phio Pharmaceuticals
    • Silence Therapeutics
    • Sirnaomics
    • Switch Therapeutics
Product Code: SR112026A2758

The global RNA interference (RNAi) drug delivery market size reached USD 117.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 504.2 Billion by 2034, exhibiting a growth rate (CAGR) of 17.04% during 2026-2034.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

KEY MARKET SEGMENTATION:

Breakup by Application:

  • Infectious Disease
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Urology
  • Metabolic Disorders
  • Others

Breakup by Technology:

  • Nanoparticle Drug Delivery
  • Pulmonary Drug Delivery
  • Nucleic Acid Drug Delivery
  • Aptamer Drug Delivery

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The report provides a comprehensive analysis of the competitive landscape in the global RNA interference (RNAi) drug delivery market with detailed profiles of all major companies, including:

  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Calando Pharmaceuticals Inc
  • Ionis Pharmaceuticals, Inc.
  • Phio Pharmaceuticals
  • Silence Therapeutics
  • Sirnaomics
  • Switch Therapeutics

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global RNA Interference (RNAi) Drug Delivery Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Infectious Disease
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cardiology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oncology
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Neurology
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Ophthalmology
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Urology
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Metabolic Disorders
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Nanoparticle Drug Delivery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Pulmonary Drug Delivery
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Nucleic Acid Drug Delivery
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Aptamer Drug Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Alnylam Pharmaceuticals, Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Arrowhead Pharmaceuticals, Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 Calando Pharmaceuticals Inc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Ionis Pharmaceuticals, Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Phio Pharmaceuticals
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Silence Therapeutics
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Sirnaomics
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Switch Therapeutics
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: RNA Interference (RNAi) Drug Delivery Market: Major Drivers and Challenges
  • Figure 2: Global: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Application (in %), 2025
  • Figure 4: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Technology (in %), 2025
  • Figure 5: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Region (in %), 2025
  • Figure 6: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 7: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: North America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: North America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: United States: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: United States: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Canada: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Canada: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: China: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: China: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Japan: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Japan: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: India: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: India: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: South Korea: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: South Korea: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Australia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Australia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Indonesia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Indonesia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Europe: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Europe: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Germany: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Germany: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: France: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: France: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: United Kingdom: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: United Kingdom: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Italy: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Italy: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Spain: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Spain: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Russia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Russia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Latin America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Latin America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Brazil: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Brazil: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Mexico: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Mexico: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Global: RNA Interference (RNAi) Drug Delivery Industry: SWOT Analysis
  • Figure 80: Global: RNA Interference (RNAi) Drug Delivery Industry: Value Chain Analysis
  • Figure 81: Global: RNA Interference (RNAi) Drug Delivery Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: RNA Interference (RNAi) Drug Delivery Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 3: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: RNA Interference (RNAi) Drug Delivery Market Structure
  • Table 6: Global: RNA Interference (RNAi) Drug Delivery Market: Key Players